SBH Stock Overview
Through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sangui Biotech International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.002 |
| 52 Week High | €0.009 |
| 52 Week Low | €0.002 |
| Beta | -0.33 |
| 11 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | -77.78% |
| 33 Year Change | -90.48% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -77.8% | -17.2% | 8.2% |
Return vs Industry: SBH underperformed the German Biotechs industry which returned -24.1% over the past year.
Return vs Market: SBH underperformed the German Market which returned 0.5% over the past year.
Price Volatility
| SBH volatility | |
|---|---|
| SBH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: SBH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SBH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Thomas Striepe | www.sanguibiotech.com |
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Sangui Biotech International, Inc. Fundamentals Summary
| SBH fundamental statistics | |
|---|---|
| Market cap | €419.80k |
| Earnings (TTM) | -€40.48k |
| Revenue (TTM) | €109.71k |
3.8x
P/S Ratio-10.4x
P/E RatioIs SBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBH income statement (TTM) | |
|---|---|
| Revenue | US$117.44k |
| Cost of Revenue | US$0 |
| Gross Profit | US$117.44k |
| Other Expenses | US$160.77k |
| Earnings | -US$43.33k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00021 |
| Gross Margin | 100.00% |
| Net Profit Margin | -36.89% |
| Debt/Equity Ratio | -72.3% |
How did SBH perform over the long term?
See historical performance and comparison